Owonikoko, T. K., Papadopoulos, K. P., Johnson, M. L., Gil Martin, M., Moreno, V., Salama, A. K. S., … Babiker, H. M. (2018). Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data. In Journal of Clinical Oncology (Vol. 36, pp. 9557–9557). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.9557

Owonikoko, Taofeek Kunle, Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Marta Gil Martin, Victor Moreno, April K. S. Salama, Emiliano Calvo, et al. “Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.” In Journal of Clinical Oncology, 36:9557–9557. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.9557.

Owonikoko TK, Papadopoulos KP, Johnson ML, Gil Martin M, Moreno V, Salama AKS, et al. Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 9557–9557.

Owonikoko, Taofeek Kunle, et al. “Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 9557–9557. Crossref, doi:10.1200/jco.2018.36.15_suppl.9557.

Owonikoko TK, Papadopoulos KP, Johnson ML, Gil Martin M, Moreno V, Salama AKS, Calvo E, Yee NS, Safran H, González-Martín A, Aljumaily R, Mahadevan D, Niu J, Mohan KK, Li J, Stankevich E, Lowy I, Fury MG, Babiker HM. Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 9557–9557.